Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C 134

Next Previous
Drug Profile

C 134

Alternative Names: C-134; chimeric oHSV; Chimeric Oncolytic Herpes Simplex Virus; IRS-1 HSV C134; MB-108

Latest Information Update: 18 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nationwide Children's Hospital; University of Alabama at Birmingham
  • Developer Gateway for Cancer Research; Nationwide Children's Hospital; University of Alabama at Birmingham
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma
  • No development reported Anaplastic astrocytoma

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Glioblastoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 07 Nov 2024 C 134 receives Orphan Drug status for Glioma in USA
  • 26 Sep 2024 University of Alabama at Birmingham plans a phase I trial for Astrocytoma and Glioblastoma (Recurrent, Second line therapy or greater) in USA (Intratumoural) (NCT06614855)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top